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The availability of genome sequences obtained using
next-generation sequencing (NGS) has revolutionized
the field of infectious diseases. Indeed, more than
38,000 bacterial and 5,000 viral genomes have been
sequenced to date, including representatives of all
significant human pathogens. These tremendous
amounts of data have not only enabled advances in
fundamental biology, helping to understand the
pathogenesis of microorganisms and their genomic
evolution, but have also had implications for clinical
microbiology. Here, we first review the current
achievements of genomics in the development of
improved diagnostic tools, including those that are
now available in the clinic, such as the design of PCR
assays for the detection of microbial pathogens,
virulence factors or antibiotic-resistance determinants,
or the design of optimized culture media for
‘unculturable’ pathogens. We then review the
applications of genomics to the investigation of
outbreaks, either through the design of genotyping
assays or the direct sequencing of the causative
strains. Finally, we discuss how genomics might
change clinical microbiology in the future.identification of virulence and antibiotic-resistance mecha-The impact of next-generation sequencing in
infectious disease diagnostics
Infectious diseases are one of the leading causes of human
mortality worldwide [1]. Therefore, accurate diagnostic
methods are required to optimize the clinical management
of infected patients. However, the gold standard for the
diagnosis of infectious diseases has long been the cul-
ture in growth-supporting media, including the isola-
tion, identification and antibiotic-susceptibility testing* Correspondence: didier.raoult@gmail.com
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unless otherwise stated.of the causative microorganism. Currently, this diagnos-
tic scheme takes a minimum of 24 hours. The introduc-
tion of the polymerase chain reaction (PCR) [2] method
in the 1980s resulted in the development of a multitude
of diagnostic tools that helped improve the efficiency of
diagnostics and the characterization of infectious-
disease agents by detecting and identifying their DNA.
However, the design of these assays remained mostly
empirical, being notably based on the use of the 16S
rRNA gene [3], until bacterial genome sequencing be-
came a reality in the mid-1990s [4]. Microbial genomics,
enabling a rational design of most molecular assays by
selecting molecular targets according to their objective,
has now had a major impact on the diagnosis and pre-
vention of infectious diseases, with detection and identi-
fication of pathogens being directly performed within
specimens without the need for culture [5].
Since 2005, the development of next-generation sequen-
cing (NGS), together with decreasing costs for sequencers
and reagents, has democratized genomics (Table 1) [6]. Cur-
rently, a bacterial genome sequence can be obtained within
a few days for less than US$500 [6], and more than 38,000
genome sequences are available in public databases [7].
NGS has had many applications in medical microbiology,
including the design of diagnostic and genotyping tools, the
nisms and the development of specific culture media [8-12].
Here, we review the most relevant applications of gen-
omics to the fields of molecular detection, identification
and genotyping of infectious-disease agents, detection of
virulence and antibiotic-resistance markers, design of
culture media and investigation of outbreaks (Table 2;
Figure 1), including those that are already available in
clinical microbiology laboratories, and we offer our
thoughts on how genomics might change clinical micro-
biology in the future.Detection of pathogens in clinical specimens
Rapid detection and identification of infectious agents in
clinical specimens are mandatory in order to implementl Ltd. The licensee has exclusive rights to distribute this article, in any medium,
this time, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Technology, platforms and features of the currently available sequencing methods
Sequencing
technology
Platform Mb/runa Time/run Read length
(bp)
Limits Applications
Sanger di-deoxy
nucleotide sequencing
Capillary sequencers,
for example, Life
Technologies ABI3730
0.44 7 hours 650-800 Cost, need for high DNA
amounts, cloning step
De novo sequencing
Pyrosequencing Roche (454) GS-FLX 700 24 hours 700 Difficulty in disambiguating
repeat regions, misincorporation
of excess nucleotides
De novo sequencing
Roche (454) GS Junior 35 4 hours 250
Sequencing by
synthesis
Illumina Genome
Analyzer II
95 × 103 14 days 2 × 150 Limited paired-end and
targeted sequencing
Resequencing
Illumina Hi Seq2500 6 × 105 11 days 2 × 100 Resequencing
Illumina MiSeq 15 × 103 56 hours 2 × 300 De novo sequencing,
resequencing
Ligation-based
sequencing
Life Technologies
SOLID 5500
32 × 103 15 days 50 + 35 Specific sequence format,
difficult sequence assembly
Resequencing
Semiconductor
sequencing
Ion Torrent PGM 200 4 hours 200-400 Artificial insertions or deletions in
mononucleotide repeats
Resequencing
Ion Torrent Proton 2.5 × 103 4 hours 100-200 Resequencing
SMRT technology Pacific Biosciences
PacBio RSII
0.5-1 × 103 4 hours 103-104 Substitution errors De novo sequencing
and genome structure
Ionic current sensing Oxford Nanopore
Technologies
NA No fixed
run-time
104-5 × 104 NA De novo sequencing
MinION
aAbbreviations: NA, data not available.
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tection assay should both be sensitive, specific and rapid
to maximize the chances of patient recovery and be able
to minimize the occurrence of clinical complications.
Since its development in 1983, PCR remained the
most widely used molecular method in clinical micro-
biology, notably for detection of microorganisms in clin-
ical specimens, until 1996 when real-time PCR (RT-
PCR) was developed. In contrast to long-established
culture-based diagnostic methods, PCR enabled identifi-
cation of microorganisms regardless of their culturability
and was, therefore, especially valuable in patients who
had received antibiotics before sampling or those in-
fected by fastidious microorganisms - that is, microor-
ganisms that do not grow in the usual culture conditions
[3]. However, early PCR assays were empirically designed
and often targeted a gene common to all bacteria, thus
allowing the detection of any species (for example, the
rRNA operon or the groEL gene). Although these broad-
range PCR assays enabled the discovery of many human
pathogens [13], they suffered from various drawbacks, in
particular a lack of sensitivity, specificity and discrimin-
atory power among bacterial species [14]. By contrast,
RT-PCR, targeting shorter fragments and using a fluor-
escent probe, greatly improved the speed, sensitivity and
specificity of detection, in particular when coupled to
the rational selection of PCR targets in genomic se-
quences according to the experimental objective and the
degree of specificity required (genus-, species-,
subspecies-, strain- or gene-specific) [15-17]. As thegenomes from more than 37,000 bacterial strains are
currently available, including those of all major human
pathogens, it is now possible for clinical microbiologists
to design specific PCR assays according to their needs
by using the available tools. As examples, Marshall de-
veloped ‘PerlPrimer’, a software enabling the design of
target-specific PCR or RT-PCR primers [15], Pritchard
and colleagues proposed an alignment-free method for
designing strain-specific primers for Escherichia coli
O104:H4 [18], and Hung and associates designed a step-
wise computational approach mixing several publicly
available softwares to identify species-specific signatures
in whole-genome sequences [17]. Using Streptococcus
pyogenes as a model, Hung and colleagues designed and
tested the validity of 15-signature-derived primer sets,
including nine that were highly species-specific in vitro
[17]. In addition, RT-PCR made possible the develop-
ment of syndrome-driven molecular diagnosis in which
assays detecting the most common etiological agents of
a given syndrome are tested concomitantly [19]. In a re-
cent study, Sokhna and colleagues described the use of a
syndrome-driven strategy for the point-of-care diagnosis
of febrile illness [20]. This type of diagnostic method has
the advantage of testing, in a short time and a limited
number of specimens, the most common causative
agents of a given syndrome and can be especially valu-
able, for example, in the diagnosis of meningitis,
pneumonia, endocarditis, pericarditis or sexually transmit-
ted diseases. Thus, it enables a more efficient management
of patients by enabling an earlier commencement of
Table 2 Current applications of high-throughput genome sequencing in clinical microbiology
Objective Methods Applicationsa Examples [references]
Pathogen detection Identification of target fragments and PCR primer design Mycobacterium
paratuberculosis [15]
Streptococcus pyogenes [17]
Syndrome-based detection RT-PCR Febrile illness [20]
Multiplex RT-PCR Tuberculosis [8]
Microarray Pneumonia [22]
Highly sensitive molecular detection PCR targeting multi-copy
targets
Whipple’s disease [23]
Suicide PCR Rickettsioses [24]
Genotyping DNA banding methods Pulsed-field gel electrophoresis,
PCR-RFLP
Yersinia pestis [9]
Presence/absence of genes RT-PCR Acinetobacter baumannii [29]
Presence/absence of repeats MLVA Mycobacterium tuberculosis [32]
Presence/absence of point mutations SNP detection Bacillus anthracis [35]
Whole-genome typing Microarray Escherichia coli [44]
Genome sequencing Staphylococcus aureus [61]
Multiple gene sequencing MLST Escherichia coli [49]
Multiple non-coding fragment sequencing MST Rickettsia species [56]
Detection of virulence
markers
Comparison of virulent/avirulent strains Yersinia pestis [10]
Identification of lateral gene transfer Salmonella Enterica [73]
Search for known virulence factors in public databases Campylobacter species [77]
Detection of antibiotic
resistance
Comparison of resistant/susceptible strains Streptococcus pneumoniae [96]
Detection of antibiotic resistance markers in clinical
isolates and specimens
RT-PCR Staphylococcus aureus [100]
Culture medium design Detection of defective metabolic pathways Design of specific culture media Tropheryma whipplei [12]
Outbreak investigation Genome comparison WGS Escherichia coli [118]
aAbbreviations: bp, base pair; Mb, megabase; MLST, multi-locus sequence typing; MLVA, multiple variable number tandem repeat analysis; MST, multi-spacer
typing; RFLP, restriction fragment length polymorphism; RT-PCR, real-time polymerase chain reaction; SNP, single nucleotide polymorphism; WGS,
whole-genome sequencing.
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also allowed the design of multiplex PCR assays enabling
simultaneous detection and discrimination of various mi-
croorganisms, as has been the case for members of the
Mycobacterium tuberculosis complex and Mycobacterium
canettii [8]. This is also true for microarrays, some of
which can enable the detection and identification of more
than 2,000 viral and 900 bacterial species at once [21]. Nso-
for recently reviewed the applications of microarrays to the
syndrome-based diagnosis of infectious diseases, some of
which, such as the ResPlex II Panel v2.0 (Qiagen, Hilden,
Germany) and the FilmArray Respiratory Panel (BioMerieux,
Marcy L’Etoile, France) for respiratory infections, are com-
mercially available [22].
In addition to the development of highly specific PCR
assays, the study of genomic sequences enabled the
optimization of the sensitivity of detection, either byselecting a gene or fragment of noncoding DNA present
as several copies in the genome [23] or by designing
nested PCR assays targeting previously unused genomic
fragments [24]. Fenollar and colleagues identified a
seven-copy fragment in the genome from the bacterium
Tropheryma whipplei and demonstrated that a RT-PCR
assay targeting this repeated fragment was significantly
more sensitive than assays targeting a single-copy frag-
ment [23]. By contrast, Drancourt and colleagues devel-
oped a strategy named 'suicide PCR' that is based on
nested-PCR assays targeting genome fragments that had
never been used as PCR targets previously and that will
be targeted only once with single-use primers [25].
These authors also demonstrated a higher sensitivity of
their method over regular PCR. Targeting multicopy
fragments was demonstrated to be highly sensitive for
the detection of Q fever, Whipple’s disease, brucellosis,
Figure 1 Applications of bacterial genomics to the management of infectious diseases. Genome sequence analysis has enabled the
development of various clinical-microbiology tools for pathogen detection, identification or genotyping by identification of sequence fragments
specific at distinct taxonomic levels (genus, species, strain, clone), for the detection of genes associated with antibiotic resistance or virulence and
for the identification of deficient metabolisms to aid the development of optimized culture media. However, whole-genome sequencing, by
giving access to the full genetic repertoire of an isolate, has demonstrated an undisputed discriminatory power for deciphering outbreaks of
infectious diseases.
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Neisseria meningitidis, whereas ‘suicide PCR’ was suc-
cessful in detecting Yersinia pestis from dental speci-
mens of ancient plague outbreaks and Rickettsia spp. in
various arthropod-borne diseases [24,25].
To date, several genome-based PCR tests have become
commercially available. These include the LightCycler
SeptiFast (Roche, Mannheim, Germany) and GeneXpert
(Cepheid, Sunnyvale, CA, USA) systems that offer multi-
plexed detection of the various pathogens potentially in-
volved in a given infectious syndrome. The latter system
also enables simultaneous discrimination of M.tuberculosis complex species and detection of rifampicin
resistance. Alternative assays are based on various detec-
tion methods for PCR products, as is the case for the
ResPlex II Panel (Qiagen, Hilden, Germany) and Film
Array (BioMerieux), in which PCR amplicons are hy-
bridized to a microarray for the syndrome-based detec-
tion of pathogens, the GenoType MTBDRplus assay
(Hain Lifescience, Nehren, Germany) that combines
PCR and hybridization to a strip to detect antibiotic re-
sistance in M. tuberculosis, and the PLEX-ID (Abbott,
Abbott Park, IL, USA), in which broad-range and clade-
specific PCR products are identified through using
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system enables screening human specimens for bacteria,
viruses, fungi, protozoa and several antibiotic-resistance-
associated genes [26].
However, although PCR and, more recently, RT-PCR
have revolutionized the diagnosis of infectious diseases
by reducing the time to diagnosis and increasing the de-
tection sensitivity, several challenges remain, including
the spectrum of detected agents, which is limited by the
specificity of the assays used. However, thanks to their
decreasing cost, the development of syndrome-based
multiplex PCR assays or microarrays is likely to increase
in the coming years. Alternatively, NGS, already known
to be used for genotyping purposes in clinical microbiol-
ogy, might also be increasingly used for clinical detec-
tion of pathogens, as was recently described for the
diagnosis of a case of neuroleptospirosis [27].
Genotyping
In situations when understanding the source and spread of
microorganisms is crucial, as is the case for outbreaks
caused by multidrug-resistant or hypervirulent bacteria
and nosocomial or pandemic infections, a higher discrim-
inatory power is needed to be able to trace pathogens at
the strain level. Identifying bacteria at the strain level - or
bacterial strain typing - is particularly important for epi-
demiological surveillance of infections. Strain typing also
has applications in studying bacterial population dynamics.
Over the past three decades, molecular typing (or molecu-
lar fingerprinting) methods have largely superseded pheno-
typic methods, including the morphology of colonies on
various culture media, biochemical tests, serology, killer
toxin susceptibility and pathogenicity, which exhibit insuf-
ficient discriminatory power, inability to quantify genetic
relationships between isolates, limited reagent availability,
poor intra- and inter-laboratory reproducibility and diffi-
culties in comparing results obtained in different laborator-
ies. In a similar fashion as described for PCR assay design,
genomic sequences can be a source of genotyping targets.
Molecular typing methods can be classified as non-
sequence-based and sequence-based genotyping methods,
depending on their design (Figure 2). Non-sequence-based
genotyping methods include pulsed-field gel electrophor-
esis (PFGE), PCR-restriction fragment length polymorph-
ism (PCR-RFLP), multiple-locus variable-number tandem-
repeat analysis (MLVA), single-nucleotide polymorphisms
(SNPs) and microarrays. Sequence-based genotyping
methods include multilocus sequence typing (MLST), mul-
tispacer sequence typing (MST) and whole-genome se-
quence typing. The choice of genotyping method should
be made according to the population structure of the in-
vestigated microorganism. This is particularly crucial for
clonal bacteria, such as M. tuberculosis or Bacillus anthra-
cis, for which structural genes are poorly polymorphic andPCR-RFLP or MLSTare inadequate, whereas MLVA is able
to discriminate among strains [28].
Non-sequence-based genotyping methods
PFGE and PCR-RFLP have long been considered as 'gold
standard' genotyping methods. These methods are DNA-
banding-pattern-based methods that compare the electro-
phoretic profiles of restriction-enzyme-cut genomes or
PCR-amplified genes from various strains. Initially, these
methods relied on uncharacterized genomic differences or
empirically selected target genes. By contrast, genome se-
quences, as was the case for M. tuberculosis or Y. pestis [9],
can be used to rationally improve the sensitivity and
specificity of PFGE or PCR-RFLP by enabling the ‘in
silico’ prediction of the most appropriate restriction pro-
files of rare-cutter enzymes for a given bacterium.
In an alternative approach, Yang and colleagues have
used genomics to design the ‘Pan-PCR’ software, dedi-
cated to the identification of strain-specific PCR targets
in genome sequences in a ‘presence/absence’ mode, that
is, the amplification of a series of unrelated genes that
were differentially present in the genomes from the stud-
ied strains [29]. As an example, in Acinetobacter bau-
mannii, the presence or absence of six genetic loci, as
determined by six locus-specific PCR assays, discrimi-
nated 29 tested strains [29]. Such a method is rapid, easy
to perform and only requires a real-time thermal cycler,
but it might not be adapted to species with highly con-
served genomes such as B. anthracis in which the gene
content does not vary among strains.
Another non-sequence-based genotyping method that
benefited from the availability of genome sequences is
MLVA. This method is based on the determination of
the number and length of variable number of tandem re-
peats (VNTRs) present in a genome and is applicable to
a variety of pathogens [30,31]. Currently, MLVA is a ref-
erence genotyping method for many bacteria, such as M.
tuberculosis [28,32], and has also been used to investi-
gate outbreaks of infections, as was demonstrated by
Paranthaman and colleagues, who accurately identified
the source of a multidrug-resistant Salmonella enterica
serovar Typhimurium outbreak that occurred in England
in 2011 [31]. MLVA is a rapid, easy-to-perform, afford-
able and reproducible genotyping method with high dis-
criminatory power, but it has been demonstrated to be
non-adaptable for some species, such as Mycoplasma
hyopneumoniae, which lacks tandem repeats [33], and in
long-term epidemiology for Mycobacterium leprae in
which variations in the VNTR pattern were observed
not only between isolates but also between specimens
from the same patient [16].
The detection of single nucleotide polymorphisms
(SNPs), another widely used typing method for bacteria,
has also been improved through using genome sequences.
Figure 2 (See legend on next page.)
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Figure 2 Principles of genome-based genotyping methods. By genomic comparison, investigators can identify specific sequence signatures
that can be used in non-sequence-based methods (DNA banding-pattern-, PCR- or hybridization-based methods) or sequence-based methods
(partial or complete genome sequencing). MLST, multi-locus sequence typing; MLVA, multiple locus variable number tandem repeat analysis; MST,
muti-spacer sequence typing; PCR-RFLP, PCR-restriction fragment length polymorphism; PFGE, pulsed-field gel electrophoresis; RFLP, restriction
fragment length polymorphism; SNP, single nucleotide polymorphism.
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strains of a given species, has enabled the genotyping of
several bacterial pathogens [9,34-39], including Coxiella
burnetii [40]. Using SNP genotyping, Huijsmans and col-
leagues identified five genotypes of C. burnetii that were
involved in the large outbreak of Q fever that occurred in
the Netherlands between 2007 and 2012 [40]. By compari-
son with other genotyping methods, SNP-based methods
are rapid, sensitive, easy to perform and unambiguous in
result interpretation. However, it should be noted that
interpreting SNP genotyping data is highly dependent on
the algorithm, the reference sequence and the sequencing
platform used, which highlights a need for standardization
of the methods used.
Genome-based DNA microarrays, an intermediate be-
tween non-sequence-based and sequence-based methods,
contain probes specific for some or all genes present in a
genome [41]. This method enables simultaneous strain
comparisons at a whole-genome level. It can be automated
and is a fast, sensitive and high-throughput genotyping
tool [16,42]. Genome-based DNA microarrays were devel-
oped to genotype a number of human pathogens, includ-
ing Escherichia coli [43], for which Geue and colleagues
were able to discriminate 446 Shiga-toxin-producing E.
coli [44]. DNA microarrays can also be used to detect and
identify microorganisms in complex floras [30,45]. How-
ever, although highly discriminatory, microarray-based
methods suffer from the major drawback that they cannot
identify genetic fragments for which no probe is used.
Sequence-based genotyping methods
By comparison with non-sequence-based methods, sequence-
based genotyping has the major advantage of being highly
reproducible because the sequence fragments on which it
is based are stored in public databases. Sequence-based
genotyping methods can rely on the selection of one or
several genomic targets or on the whole genome sequence.
Single-locus sequence-typing methods require the in silico
identification of a highly variable gene, such as the
coagulase- and protein-A-encoding genes that are the gen-
omic targets of coa or spa typing, respectively, two broadly
used tools for Staphylococcus aureus [46,47].
MLST, developed in 1998, is one of the most frequently
used sequence-based genotyping methods. It is based on
the combination of genotypes obtained from several indi-
vidual genes, usually housekeeping genes, for characteriz-
ing bacterial strains [48]. Genome-sequence-designedMLST assays have been useful for typing pathogens that
have highly variable genomes among strains, such as E.
coli, N. meningitidis or S. aureus [30,49,50], but they dem-
onstrated limited discriminatory power among those bac-
teria with highly conserved genomes such as B. anthracis
[30]. In 2012, rMLST, based on a combination of 53 ribo-
somal protein subunits, was demonstrated to discriminate
strains within the genus Neisseria [51]. However, whole-
genome MLST, incorporating more than 500 loci, was able
to identify bacteria at the clone level [52]. This method is
especially valuable when implemented with the BIGSdb
platform that enables standardization of data [53]. In a
similar fashion, multi-spacer typing (MST), based on the
assumption that intergenic spacers are more variable than
genes owing to a lower selection pressure, combines se-
quences from the most variable intergenic spacers between
aligned genomes of bacterial strains instead of genes [54].
First developed for Y. pestis [54], MST has also been effi-
cient at typing strains from various other bacteria, includ-
ing C. burnetii [30,55-57]. Glazunova and colleagues, by
using a combination of 10 intergenic spacer sequences,
were able to classify 159 C. burnetii isolates within 30 dis-
tinct genotypes [55]. MST was demonstrated to be more
discriminatory than MLST for R. conorii strains [56].
However, bacterial whole-genome sequencing (WGS)
using NGS, by giving access to the whole genetic con-
tent of a strain, is the ultimate discriminatory sequence-
based genotyping method and has already demonstrated
its usefulness for epidemiological investigations, showing
the rapid global transmission of infectious diseases
[38,58,59] (Table 3). WGS was used to compare 86 hu-
man M. tuberculosis isolates from a German outbreak
and has demonstrated its superiority over other genotyp-
ing methods for tracing and investigating micro-
epidemics [60,61]. In 2010, WGS was used to study 63
strains of methicillin-resistant Staphylococcus aureus
(MRSA) from various countries and enabled reconstruc-
tion of intercontinental transmissions over four decades
as well as the potential transmission within a hospital
environment [38]. WGS was also used to investigate the
cholera outbreak in Haiti that occurred in 2010 [58,59],
revealing that Haitian strains were closely related to strains
from Nepal. These pioneering studies demonstrated the
potential of WGS for retrospective genotyping. The major
challenge is to make WGS a genotyping tool during the
course of outbreaks, and for this it will be necessary to
facilitate access to sequencing platforms.
Table 3 Examples of infectious disease outbreaks for which next-generation sequencing has been used
Causative agent Date of
outbreaka
Country Setting NGS platform Impact on disease control and/or findings Reference
Multi-drug resistant
Acinetobacter baumannii
2009 UK Hospital Roche GS-FLX Proof of patient-to-patient transmission [114]
Bordetella pertussis 2012 USA Community PacBio RS Identification of several concomitant clones [131]
Clostridium difficile 2007-2011 UK Hospital and
community
Illumina Only one-third of cases were acquired from
symptomatic patients
[132]
Carbapenem-resistant
Enterobacter cloacae
2008-2009 UK Hospital Illumina MiSeq Retrospective identification of two distinct strains [133]
Vancomycin-resistant
Enterococcus faecium
NA UK Hospital Illumina MiSeq Retrospective identification of the clonality of the
causative strain
[133]
Escherichia coli O104:H4 2011 Germany Community Ion Torrent
PGM, PacBio
RS
Identification of the source of infection [134,135]
Francisella tularensis
holarctica
2010 Sweden Community Ion Torrent
PGM, PacBio
RS
Retrospective identification of several clones [136]
Carbapenemase-producing
Klebsiella pneumoniae
2012 Nepal Hospital PacBio RS,
Illumina HiSeq
Identification of a clone responsible for three
distinct outbreaks
[137]
Legionella pneumophila 2012 Canada Community Illumina MiSeq Identification of the source of infection [138]
Listeria monocytogenes 2008 Canada Community Roche GS-FLX Retrospective identification of three clones
responsible for a nationwide outbreak
[139]
Mycobacterium abscessus 2007-2011 UK Cystic fibrosis
center
Illumina HiSeq Proof of patient-to- patient transmission [140]
Mycobacterium tuberculosis 2006-2008 Canada Hospital Illumina
Genome
Analyzer II
Retrospective identification of two concomitant
outbreaks
[141]
Mycobacterium tuberculosis 2010 UK Community Illumina MiSeq Identification and treatment of contact patients [119]
Neisseria meningitidis 1997 UK Hospital Illumina
Genome
Analyzer II
Retrospective identification of the causative clone [142]
Salmonella Newport 2011 Europe Community Illumina HiSeq Confirmation of watermelons as source of
international spread of a Salmonella newport clone
[143]
Salmonella Enteritidis 2010-2012 USA Hospital IonTorrent
PGM
Retrospective and prospective identification of a
single clone responsible for the outbreak
[144]
Methicillin-resistant
Staphylococcus aureus
2009 USA Pediatric
hospital
Illumina MiSeq Retrospective identification of the causative clone
and its resistome
[61]
Methicillin-resistant
Staphylococcus aureus
2011 UK Hospital Illumina HiSeq Identification of carriage by a staff member [145]
Staphylococcus aureus 2011 USA Hospital Illumina HiSeq Proof of absence of patient-to-patient transmission [146]
Vibrio cholerae 2010 Haiti Community PacBio RS Identification of the source of the causative clone [59]
Vibrio cholerae 2012 Guinea Community Illumina MiSeq Identification of the source of the causative clone [147]
aAbbreviations: NA, data not available.
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In addition to identifying bacteria at various taxonomic
levels, WGS offers the opportunity to detect various
genetic markers, such as virulence factors or antibiotic
resistance-associated genes. Identifying and characteriz-
ing the virulence factors of pathogens are crucial for un-
derstanding the pathogenesis of the diseases that they
cause and for developing dedicated molecular tools to
detect specific virulence markers. However, among the
currently known virulence markers, only toxins areimportant for optimizing the management of patients, as
these agents are able to cause hospital outbreaks of se-
vere infections with high mortality rates, such as the hy-
pervirulent ribotype O27 Clostridium difficile [62], or
because the administration of antibiotics can have a sig-
nificant impact on the outcome. This is notably the case
for S. aureus, in which the secretion of the Panton-
Valentine leukocidin is induced by oxacillin or depressed
by clindamycin [63,64], for the Shiga-toxin production
in E. coli that is stimulated by β-lactams, sulfonamides
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which fluoroquinolones upregulate a toxin-antitoxin
module [66]. Therefore, determining the toxinic reper-
toire of strains of selected bacterial species can be cru-
cial for effective clinical management.
Genomics has played an important role in the identifi-
cation of virulence factors in bacteria. Three main strat-
egies are used to identify virulence-factor-encoding
genes in genomes [67]: first, comparison of genomes
from strains or species exhibiting diverse degrees of
virulence; second, identification of laterally transferred
genomic islands, assuming that virulence genes are often
acquired by this mechanism [67]; and, third, running the
genome against databases of known virulence markers.
The first approach was used in studies between Y. pestis,
the causative agent of plague, and the less-virulent but
closely related species Y. pseudotuberculosis [10], be-
tween a pathogenic strain of E. coli O157:H7 and a non-
pathogenic laboratory strain of E. coli K-12 [68,69], be-
tween a highly virulent Staphylococcus epidermidis caus-
ing community-acquired endocarditis and commensal
strains [70], and between Klebsiella pneumoniae strains
[71]. The second strategy enabled the identification of
pathogenicity islands in various species [72-75], such as
E. coli or S. aureus. The third method enabled identifica-
tion of virulence genes in a variety of species [76-87],
notably Listeria monocytogenes and M. tuberculosis. All
three strategies are complementary but cannot replace
functional studies for confirmation of the real role of the
identified virulence factors in pathogenesis.
Paradoxically, genomic comparisons have also ques-
tioned the paradigm of virulence by gene acquisition. In
many genera, genome reduction, rather than acquisition
of additional genetic material, can be associated with in-
creased virulence, as many of the most virulent bacterial
pathogens have smaller genomes than closely related
species [88]. The comparison of rickettsial genomes
showed that Rickettsia prowazekii, the agent of epidemic
typhus, the deadliest rickettsiosis, had the smallest gen-
ome in this genus (Figure 2) [89]. Similar findings were
reported for Mycobacterium ulcerans [90]. In addition,
the presence of ‘non-virulence’ genes was described as
discriminating Shigella dysenteriae from E. coli or Y. pes-
tis from Y. pseudotuberculosis [88]. In Y. pestis, for ex-
ample, the loss of the rcsA and nghA genes, which
encode a repressor of biofilm synthesis and an inhibitor
of biofilm formation, respectively, might have contrib-
uted to a more efficient flea-borne transmission [91].
Therefore, the pathogenic repertoire of a bacterium
should not only take into account the presence or ab-
sence of virulence factors but also of ‘non-virulence’
genes.
However, it should be noted that the virulence of a
bacterial strain might not systematically be predictedfrom its genome sequence, in particular when the identi-
fied virulence markers are not expressed. Indeed, Priest
and colleagues could overcome this limitation by using
systems biology to predict virulence in S. aureus [92].
Briefly, these authors not only considered the presence
of virulence genes but also took into account the known
regulatory networks of these genes.
Detection of antibiotic resistance
Currently, antimicrobial resistance is a major public
health concern worldwide, especially as some pathogenic
multidrug-resistant bacteria are already resistant to all
antibiotics in use in the clinic [93]. Detection of bacterial
resistance determinants, and identification of new ar-
rangements of known resistance genes, as well as new
putative resistance markers can be achieved with WGS.
This might help predict the resistance phenotype, set up
enhanced in-hospital infection-control measures, adapt a
specific therapy and enable the identification of
resistance-causing genes or mutations that could be de-
tected by PCR from clinical isolates or specimens and
serve as targets for routine detection tools [94]. The
strategies for identifying resistance markers are very
similar to those aimed at identifying virulence genes [6].
However, as incomplete data link genotype to phenotype
in terms of drug resistance, WGS genomic-based detec-
tion is particularly suited for antibiotics for which
resistance-associated mutations or genes are known and
notably for fastidious bacteria such as M. tuberculosis
[95].
Genomic comparisons of phenotypically resistant and
susceptible strains has enabled investigation of the resis-
tome - that is, the repertoire of genetic markers associ-
ated with antibiotic resistance of multidrug-resistant
strains of Enterococcus faecium [11] and S. pneumoniae
[96]. Genome sequencing has also enabled identification
of resistance mechanisms in fastidious bacteria that ex-
press few phenotypic characteristics, as was the case for
T. whipplei, the causative agent of Whipple’s disease,
that is resistant to fluoroquinolones owing to mutations
in the gyrA and parC genes [97], Rickettsia felis, which
expresses a β-lactamase activity that was first found in
the genome [98], and M. tuberculosis, in which a puta-
tive rRNA methyltransferase might explain its resistance
to macrolide antibiotic drugs [95].
Several PCR assays used in clinical practice derive
from genomic sequences. The recent discovery of the
mecC gene - a homolog of the mecA gene encoding
methicillin resistance, responsible for false susceptibility
testing results - in the genome of a methicillin-resistant
S. aureus [99] elicited the design of specific PCR assays
[100]. The spread of carbapenemase-producing entero-
bacteriaceae also prompted the sequencing of genomes
from various MDR strains, including an NDM-1-producing
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[102], which in turn enabled the development of dedicated
PCR assays [103]. Therefore, although many genome-based
molecular tests facilitating the management of infections
have already been developed to date, there is no doubt
that WGS data will be used extensively in future assay
design.
Culturing unculturable pathogens
Despite the breakthrough of molecular methods, culture
remains the cornerstone of routine microbiology as it
provides insight into their ecology and pathogenicity.
However, a majority of microorganisms in nature are
not cultivable using standard techniques. Many fastidi-
ous bacteria grow poorly on commonly used media, and
others are considered uncultivable on axenic media, pos-
sibly owing to deficient or partial metabolic pathways.
Thus, genome sequences might enable identification of
incomplete metabolic pathways [104] and the essential
nutrients that a bacterium is unable to produce [105],
which could then be incorporated into a specifically de-
signed culture medium. T. whipplei, causing Whipple’s
disease, was the first ‘unculturable’ human pathogen
[106,107] to benefit from such an in silico design of a
culture medium. An axenic culture medium specifically
designed to contain the nine amino acids that this bac-
terium was unable to synthesize enabled its axenic
growth [12]. A similar approach was used for Xyllela fas-
tidiosa [108], Leptospirillum ferrodiazotrophum [109]
and C. burnetii [110]. Alternatively, genomics might help
improve culture media, as was the case for E. coli and
M. pneumoniae [111,112]. However, this strategy might
not be efficient for just any bacterium, as was the
case for M. leprae. Despite the many important meta-
bolic activities missing in the genome [113] of this bac-
terium, no specifically complemented axenic medium
has enabled any growth to date. However, although it
is important to improve culture methods for fastidious
microorganisms, the investigation of unusual infec-
tions or outbreaks needs rapid and informative methods
that may help influence the management of patients
and course of the outbreaks. Such progress is now
made possible by NGS.
Real-time genomics for the diagnosis of infections
or the investigation of outbreaks
The development of NGS bench-top sequencers such as
the MiSeq (Illumina) and Ion Torrent Personal Genome
Sequencer (PGM; Life Technologies) has made genome
sequencing compatible with the routine clinical-
microbiology workflow [6]. Such a strategy enables,
within a few hours, exhaustive access to the genotype
[39], virulence markers and antibiotic-resistance reper-
toire. Real-time genomics has notably been used toinvestigate several nosocomial [70,114] or community-
acquired infections [115-118] (Table 3). Sherry and col-
leagues used PGM sequencing of four MDR E. coli
strains to confirm that the nosocomial outbreak that had
occurred in a neonatal unit in Melbourne, Australia, had
been caused by a unique clone and to characterize the
resistance genes for this outbreak strain [118]. In
Germany, Mellmann and colleagues compared the ge-
nomes from two E. coli O104:H4 strains from two
hemolytic uremic syndrome outbreaks and concluded
that the strains had diverged from a common ancestor
and that NGS was suitable for the characterization of a
pathogen in the early stages of an outbreak [115]. In
both cases, genome sequences were obtained in a few
days (five and three days, respectively). These findings
demonstrated how rapid and precise genomic sequen-
cing, although limited to a few clinical-microbiology la-
boratories currently, could transform patient
management or improve hospital infection control in
routine clinical practice.
Although only a few studies to date have described a
turnaround time sufficiently short to enable WGS data
to influence the course of outbreaks [119], the increasing
number of teams using WGS for epidemiological pur-
poses (Table 3) leaves little doubt as to the likelihood of
its systematic use as a first-line tool to track and under-
stand epidemics in the near future.How will next-generation sequencing change clin-
ical microbiology?
NGS has the potential to change clinical microbiology in
several ways. First, the increasing number of genome se-
quences will enable the development of new and im-
proved pathogen-specific or syndrome-based single or
multiplexed RT-PCR assays and will aid the refinement
of DNA targets, primers and probes used in existing
tests [120]. Second, the increase in speed, decreasing
costs and discriminatory power of NGS make it an ideal
tool for routine use in diagnostic microbiology laboratories.
NGS has the potential to replace several existing tests
performed on the same isolate, notably identification of
antibiotic-resistance mechanisms, virulence determinants
and genotype, in particular for microorganisms that are
difficult to grow. As such, it is especially well suited for in-
fection control. In addition, NGS without the need for cul-
ture, in particular single-cell sequencing, might be relevant
for the routine characterization of unculturable bacteria.
Third, NGS has proven its usefulness to decipher complex
microbiotas in various metagenomic studies [121]. Recent
studies have demonstrated its ability not only to discrimin-
ate among microorganisms present in human specimens,
and thus possibly detect co-infections, but also uncover
unexpected or new pathogens [122-124].
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being a facilitated and rapid access of clinical microbiology
laboratories to sequencing platforms, and a need for stan-
dardized and fully automated sequence interpretation that
would ideally be independent of both the sequencing plat-
form and the exact species of microorganism [125-127].
Also needed is the ability to translate the data into rele-
vant information enabling microbiologists, clinicians and
public-health epidemiologists to implement control mea-
sures in real-time and alter the course of outbreaks. This
implies a constant update and curation of public databases
as well as the development of systems-biology-based soft-
wares that will enable prediction of virulence and antibiotic
resistance from genome sequences.
Conclusions and perspectives
The expansion of genomics, giving access to the ge-
nomes of virtually all human pathogens, has greatly
changed our approach regarding management of infec-
tious diseases by shedding light on their genetic diver-
sity, pathogenesis, evolution, detection and treatment.
With access to the full genetic content of microorgan-
isms, rational selection of DNA fragments has enabled
creation of a wide array of detection and typing methods
as well as specialized tools for the identification of genes
encoding factors affecting virulence or antibiotic resist-
ance. In addition, NGS methods have reached a point,
both in terms of cost and speed, where they might enter
the routine microbiology laboratory and be used rou-
tinely for the rapid sequencing of microorganisms that
exhibit unusual pathogenicity, are antibiotic-resistant or
cause outbreaks. However, the major challenge in order
to include genome sequencing in the routine workflow
of the clinical-microbiology laboratory, in addition to a
need for a multiplication of sequencing platforms, is a
clear need for improved sequence analysis, both in terms
of numbers and data handling of bioinformatic facilities,
and storage capacity, as well as homogenized gene-
function assignment.
It is likely that NGS, by permitting genome sequencing
from single cells or single colonies, will also constitute a
major step forward in the comprehension of bacterial
genome dynamics [128]. This strategy has the advantage
over other sequencing methods in that it is applicable
to microorganisms that are unculturable and/or part of
complex floras [129,130]. However, single-cell genom-
ics also currently suffers from several limitations, which
include genome amplification biases, chimeric DNA re-
arrangements and a need for the improved de novo as-
sembly of DNA sequences of previously non-sequenced
microorganisms.
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